(-) Research news (12)
(-) Carolyn M. Brown, Ph.D., FAPhA (1)
(-) Leticia R. Moczygemba, Pharm.D., Ph.D., FAACP, FAPhA (3)
(-) Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. (5)
(-) Carolyn M. Brown, Ph.D., FAPhA
(-) Leticia R. Moczygemba, Pharm.D., Ph.D., FAACP, FAPhA
(-) Somshuvra Mukhopadhyay, M.B.B.S., Ph.D.
Moczygemba and Wash Earn 2022 Kloesel Grant
Leticia "Tish" Moczygemba, Pharm.D., Ph.D. and Andrew Wash, Pharm.D. were selected as the recipients of the 2022 grant award from the Arlyn Kloesel Endowment for Excellence in Pharmacy Practice.
Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.
Improving Health Outcomes for People Experiencing Homelessness is Focus of New Study
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.
Mukhopadhyay Wins Research Excellence Award
Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.
Existing drug may help fight against the lethality of E. coli infection
New research from the lab of Division of Pharmacology and Toxicology's Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. may have discovered a way to repurpose an existing drug to fight the lethality of Shiga toxin-producing Escherichia coli (STEC) infections.